Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 1
2018 1
2019 4
2020 4
2021 3
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity.
Baumgartner F, Bamopoulos SA, Faletti L, Hsiao HJ, Holz M, Gonzalez-Menendez I, Solé-Boldo L, Horne A, Gosavi S, Özerdem C, Singh N, Liebig S, Ramamoorthy S, Lehmann M, Demel U, Kühl AA, Wartewig T, Ruland J, Wunderlich FT, Schick M, Walther W, Rose-John S, Haas S, Quintanilla-Martinez L, Feske S, Ehl S, Glauben R, Keller U. Baumgartner F, et al. Among authors: schick m. Sci Signal. 2024 Feb 20;17(824):eadc9662. doi: 10.1126/scisignal.adc9662. Epub 2024 Feb 20. Sci Signal. 2024. PMID: 38377177
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
Zhang L, Wirth M, Patra U, Stroh J, Isaakidis K, Rieger L, Kossatz S, Milanovic M, Zang C, Demel U, Keiten-Schmitz J, Wagner K, Steiger K, Rad R, Bassermann F, Müller S, Keller U, Schick M. Zhang L, et al. Among authors: schick m. EMBO Mol Med. 2023 Sep 11;15(9):e16431. doi: 10.15252/emmm.202216431. Epub 2023 Jul 24. EMBO Mol Med. 2023. PMID: 37485814 Free PMC article.
Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
Demel UM, Wirth M, Yousefian S, Zhang L, Isaakidis K, Dönig J, Böger M, Singh N, Köse H, Haas S, Müller S, Schick M, Keller U. Demel UM, et al. Among authors: schick m. Haematologica. 2023 Feb 1;108(2):555-567. doi: 10.3324/haematol.2022.280995. Haematologica. 2023. PMID: 36134453 Free PMC article.
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, Kaiser M, Schäffer I, Bamopoulos SA, Ramberger E, Murgai A, Ng YLD, Demel UM, Laue D, Liebig S, Krüger J, Janz M, Nogai A, Schick M, Mertins P, Müller S, Bassermann F, Krönke J, Keller U, Wirth M. Heynen GJJE, et al. Among authors: schick m. Blood Adv. 2023 Feb 28;7(4):469-481. doi: 10.1182/bloodadvances.2022007875. Blood Adv. 2023. PMID: 35917568 Free PMC article.
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
Demel UM, Böger M, Yousefian S, Grunert C, Zhang L, Hotz PW, Gottschlich A, Köse H, Isaakidis K, Vonficht D, Grünschläger F, Rohleder E, Wagner K, Dönig J, Igl V, Brzezicha B, Baumgartner F, Habringer S, Löber J, Chapuy B, Weidinger C, Kobold S, Haas S, Busse AB, Müller S, Wirth M, Schick M, Keller U. Demel UM, et al. Among authors: schick m. J Clin Invest. 2022 May 2;132(9):e152383. doi: 10.1172/JCI152383. J Clin Invest. 2022. PMID: 35499080 Free PMC article.
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.
Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, Illendula A, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. Doffo J, et al. Among authors: schick m. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2105691119. doi: 10.1073/pnas.2105691119. Proc Natl Acad Sci U S A. 2022. PMID: 35197278 Free PMC article.
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.
Schick M, Zhang L, Maurer S, Maurer HC, Isaakaidis K, Schneider L, Patra U, Schunck K, Rohleder E, Hofstetter J, Baluapuri A, Scherger AK, Slotta-Huspenina J, Hettler F, Weber J, Engleitner T, Maresch R, Slawska J, Lewis R, Istvanffy R, Habringer S, Steiger K, Baiker A, Oostendorp RAJ, Miething C, Lenhof HP, Bassermann F, Chapuy B, Wirth M, Wolf E, Rad R, Müller S, Keller U. Schick M, et al. Nat Commun. 2022 Jan 12;13(1):281. doi: 10.1038/s41467-021-27704-8. Nat Commun. 2022. PMID: 35022408 Free PMC article.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F. Stroh J, et al. Among authors: schick m. Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532. Blood Adv. 2022. PMID: 34768284 Free PMC article.
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Lewis R, Maurer HC, Singh N, Gonzalez-Menendez I, Wirth M, Schick M, Zhang L, Isaakidis K, Scherger AK, Schulze V, Lu J, Zenz T, Steiger K, Rad R, Quintanilla-Martinez L, Espeli M, Balabanian K, Keller U, Habringer S. Lewis R, et al. Among authors: schick m. Leukemia. 2021 Oct;35(10):2895-2905. doi: 10.1038/s41375-021-01376-1. Epub 2021 Aug 6. Leukemia. 2021. PMID: 34363012 Free PMC article.
22 results